NCT03709953

Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: Guangzhou Institute of Respiratory Disease · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Currently, there is no standard treatment for primary pulmonary lymphoepithelioid carcinoma. Apatinib is a new kind of Vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitors (TKIs). A disease-control rate of 75% was found in lung cancer patients in a phase II clinical study. Therefore, researchers hope to explore the efficacy and safety of apatinib in the treatment of primary pulmonary lymphoepithelioid carcinoma.

Detailed description

This study is a prospective, exploratory clinical trial. The purpose of this study was to evaluate the efficacy and safety of apatinib monotherapy in the treatment of primary pulmonary lymphoepithelioid carcinoma. Thirty-three cases of pulmonary lymphoepithelioid carcinoma were enrolled in this study. The primary endpoint was median progression-free survival.

Conditions

• Lung Carcinoma

Interventions

Type	Name	Description
DRUG	Apatinib	500 mg，po，QD； 28 days every cycle

Timeline

• Start date: 2018-10-19
• Primary completion: 2021-03-31
• Completion: 2021-04-30
• First posted: 2018-10-17
• Last updated: 2018-10-24

Locations

1 site across 1 country: China